Krystal Biotech price target raised to $240 from $221 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Krystal Biotech (KRYS) to $240 from $221 and keeps a Buy rating on the shares based on an adjustment to its base year, an adjustment to the fully diluted share count, increasing its projected odds of success for Vyjuvek to 100% from 95% and increasing projected peak sales expectations in the EU to $600M from $500M.